Predictive value of MMP-7 expression for response to chemotherapy and survival in patients with non-small cell lung cancer

Cancer Science

Volumn 99, Issue 11, 2008, Pages 2185-2192

  Liu, Hui ^a   Zhang, Tiantuo ^a   Li, Xiaodong ^a   Huang, Jing ^a   Wu, Benquan ^a   Huang, Xubing ^a   Zhou, Yuqi ^a   Zhu, Jiaxin ^a   Hou, Jinghui ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; FAS ANTIGEN; FAS LIGAND; GEMCITABINE; KI 67 ANTIGEN; MATRILYSIN; NAVELBINE; PACLITAXEL; PLATINUM COMPLEX; PROTEIN BAX; PROTEIN BCL 2;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RESPONSE; FEMALE; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NICK END LABELING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 7; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 55449099990     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00922.x     Document Type: Article

References (40)

1. Cosaert J, Quoix E. Platinum drugs in the treatment of non-small-cell lung cancer. Br J Cancer 2002; 87: 825-33.
2. Mantovani A, Romero P, Palucka AK, Marincola FM. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 2008; 371: 771-83.
3. Rintoul RC, Sethi T. Extracellular matrix regulation of drug resistance in small-cell lung cancer. Clin Sci (Lond) 2002; 102: 417-24.
4. Sethi T, Rintoul RC, Moore SM et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 1999; 5: 662-8.
5. Ii M, Yamamoto H, Adachi Y, Maruyama Y, Shinomura Y. Role of matrix metalloproteinase-7 (Matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp Biol Med 2006; 231: 20-7.
6. Vargo-Gogola T, Fingleton B, Crawford HC, Matrisian LM. Matrilysin (matrix metalloproteinase-7) selects for apoptosis-resistant mammary cells in vivo. Cancer Res 2002; 62: 5559-63.
7. Mitsiades N, Yu WH, Poulaki V, Tsokos M, Stamenkovic I. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res 2001; 61: 577-81.
8. Almendro V, Maurel J, Augé J et al. Role of metalloproteinase-7 in oxaliplatin acquired resistance in colorectal cancer cell lines. ASCO Meeting Abstracts 2006; 24: 20042.
9. Miyata Y, Iwata T, Ohba K, Kanda S, Nishikido M, Kanetake H. Expression of matrix metalloproteinase-7 on cancer cells and tissue endothelial cells in renal cell carcinoma: Prognostic implications and clinical significance for invasion and metastasis. Clin Cancer Res 2006; 12: 6998-7003.
10. Wang WS, Chen PM, Wang HS, Liang WY, Su Y. Matrix metalloproteinase-7 increases resistance to Fas-mediated apoptosis and is a poor prognostic factor of patients with colorectal carcinoma. Carcinogenesis 2006; 27: 1113-20.
11. Liu D, Nakano J, Ishikawa S et al. Overexpression of matrix metalloproteinase-7 (MMP-7) correlates with tumor proliferation, and a poor prognosis in non-small cell lung cancer. Lung Cancer 2007; 58: 384-91.
12. Yukiue H, Moiriyama S, Kobayashi Y et al. Clinical significance of matrix metalloproteinase-7 and Ets-1 gene expressio n in patients with lung cancer. J Surg Res 2001; 101: 242-7.
13. Leinonen T, Pirinen R, Bohm J, Johansson R, Ropponen K, Kosma VM. Expression of matrix metalloproteinases 7 and 9 in non-small cell lung cancer. Relation to clinicopathological factors, beta-catenin and prognosis. Lung Cancer 2006; 51: 313-21.
14. World Health Organization. Histological Typing of Lung Tumours, 2nd edn. Geneva: World Health Organization, 1999; 21-66.
15. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111: 1710-17.
16. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
17. Strand S, Vollmer P, van den Abeelen L et al. Cleavage of CD95 by matrix metalloproteinase-7 induces apoptosis resistance in tumour cells. Oncogene 2004; 23: 3732-6.
18. Powell WC, Fingleton B, Wilson CL, Boothby M, Matrisian LM. The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Curr Biol 1999; 9: 1441-7.
19. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: Biologic activity and clinical implications. J Clin Oncol 2000; 18: 1135-49.
20. Wilson CL, Heppner KJ, Labosky PA et al. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Natl Acad Sci 1997; 94: 1402-7.
21. Hulboy DL, Gautam S, Fingleton B, Matrisian LM. The influence of matrix metalloproteinase-7 on early mammary tumorigenesis in the multiple intestinal neoplasia mouse. Oncol Rep 2004; 12: 13-17.
22. Yu WH, Woessner JFJ, McNeish JD, Stamenkovic I. CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. Genes Dev 2002; 16: 307-23.
23. Miyamoto S, Yano K, Sugimoto S et al. Matrix metalloproteinase-7 facilitates insulin-like growth factor bioavailability through its proteinase activity on insulin-like growth factor binding protein 3. Cancer Res 2004; 64: 665-71.
24. Liu XP, Oga A, Suehiro Y, Furuya T, Kawauchi S, Sasaki K. Inverse relationship between matrilysin expression and proliferative activity of cells in advanced gastric carcinoma. Hum Pathol 2002; 33: 741-7.
25. Liu H, Huang J, Wu B, Zhou Y, Zhu J, Zhang T. Matrilysin inhibits proliferation and modulates sensitivity of lung cancer cells to FasL-mediated apoptosis. Med Oncol 2008 (Mar 14) [Epub ahead of print].
26. Harrell PC, McCawley LJ, Fingleton B et al. Proliferative effects of apical, but not basal, matrix metalloproteinase-7 activity in polarized MDCK cells. Exp Cell Res 2005; 303: 308-20.
27. Nailin H, Yasushi I, Masako K et al. MMP-7 (matrilysin) accelerated growth of human umbilical vein endothelial cells. Cancer Lett 2002; 177: 95-100.
28. Kendra JG, Zena W, Farrah K. Matrix metalloproteinases in lung: multiple, multifarious, and multifaceted. Physiol Rev 2007; 87: 69-98.
29. Ghobrial IM, Witzig TE, Alex A. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 2005; 55: 178-94.
30. Gonzalez VM, Fuertes MA, Alonso C, Perez JM. Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol 2001; 59: 657.
31. Hu D-M, Wang S-F, Feng Y-Z. Expression of matrix metalloproteinase-7 and Fas and their significances in gastric carcinoma. World J Gastroenterol 2006; 14: 3237-40.
32. Crawford HC, Scoggins CR, Washington MK, Matrisian LM, Leach SD. Matrix metalloproteinase-7 is expressed by pancreatic cancer precursors and regulates acinar-to-ductal metaplasia in exocrine pancreas. J Clin Invest 2002; 109: 1437-44.
33. Losert D, Pratscher B, Soutschek J et al. Bcl-2 downregulation sensitizes nonsmall cell lung cancer cells to cisplatin, but not to docetaxel. Anticancer Drugs 2007; 18: 755-61.
34. Kumar Biswas S, Huang J, Persaud S, Basu A. Down-regulation of Bcl-2 is associated with cisplatin resistance in human small cell lung cancer H69 cells. Mol Cancer Ther 2004; 3: 327-34.
35. Huang Z, Lei X, Zhong M, Zhu B, Tang S, Liao D. Bcl-2 small interfering RNA sensitizes cisplatin-resistant human lung adenocarcinoma A549/DDP cell to cisplatin and diallyl disulfide. Acta Biochim Biophys Sin (Shanghai) 2007; 39: 835-43.
36. Wilson LA, Yamamoto H, Singh G. Role of the transcription factor Ets-1 in cisplatin resistance. Mol Cancer Ther 2004; 3: 823-32.
37. Tan X, Egami H, Abe M, Nozawa F, Hirota M, Ogawa M. Involvement of MMP-7 in invasion of pancreatic cancer cells through activation of the EGFR mediated MEK-ERK signal transduction pathway. J Clin Pathol 2005; 58: 1242-8.
38. Andrieux LO, Fautrel A, Bessard A, Guillouzo A, Baffet G, Langouët S. GATA-1 is essential in EGF-mediated induction of nucleotide excision repair activity and ERCC1 expression through ERK2 in human hepatoma cells. Cancer Res 2007; 67: 2114-23.
39. Lin TS, Chiou SH, Wang LS et al. Expression spectra of matrix metalloproteinases in metastatic non-small cell lung cancer. Oncol Rep 2004; 12: 717-23.
40. Kawano N, Osawa H, Ito T et al. Expression of gelatinase A, tissue inhibitor of metalloproteinases-2, matrilysin, and trypsin (ogen) in lung neoplasms: An immunohistochemical study. Hum Pathol 1997; 28: 613-22.